28,744 Shares in Alpha Teknova, Inc. (NASDAQ:TKNO) Bought by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. bought a new stake in Alpha Teknova, Inc. (NASDAQ:TKNO) during the fourth quarter, Holdings Channel reports. The firm bought 28,744 shares of the company’s stock, valued at approximately $240,000.

Other institutional investors have also recently bought and sold shares of the company. Roubaix Capital LLC bought a new stake in Alpha Teknova during the third quarter valued at about $2,015,000. Point72 Asset Management L.P. acquired a new position in shares of Alpha Teknova during the 3rd quarter worth about $1,483,000. State Street Corp boosted its stake in Alpha Teknova by 249.3% during the 3rd quarter. State Street Corp now owns 76,645 shares of the company’s stock valued at $371,000 after purchasing an additional 54,700 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Alpha Teknova by 24.4% in the 3rd quarter. Geode Capital Management LLC now owns 188,173 shares of the company’s stock valued at $911,000 after buying an additional 36,914 shares during the last quarter. Institutional investors own 13.81% of the company’s stock.

Alpha Teknova Stock Up 2.5 %

Shares of TKNO stock opened at $8.35 on Thursday. Alpha Teknova, Inc. has a 12 month low of $1.15 and a 12 month high of $9.72. The company has a quick ratio of 3.94, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market cap of $445.12 million, a PE ratio of -11.28 and a beta of 0.34. The stock has a 50 day moving average of $7.90 and a 200-day moving average of $5.80.

Alpha Teknova (NASDAQ:TKNO) last released its earnings results on Thursday, November 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.04). The company had revenue of $9.58 million for the quarter, compared to analyst estimates of $9.30 million. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. During the same quarter in the previous year, the company earned ($0.34) earnings per share. On average, equities analysts predict that Alpha Teknova, Inc. will post -0.58 EPS for the current year.

Alpha Teknova Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.